Company Overview - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases [3] - The company's lead product candidate, Auxora™, has shown positive clinical results in multiple completed efficacy trials [3] - CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, California [3] Clinical Trials and Product Development - CalciMedica has announced topline data for a Phase 2b trial (CARPO – NCT04681066) in patients with acute pancreatitis and systemic inflammatory response syndrome [3] - The company completed a Phase 2 trial (CARDEA – NCT04345614) in patients with COVID pneumonia [3] - Currently, CalciMedica is conducting a Phase 2 trial (KOURAGE – NCT06374797) in patients with acute kidney disease and associated acute hypoxemic respiratory failure [3] - The company is also supporting an ongoing Phase 1/2 trial (CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity [3] Upcoming Events - Rachel Leheny, Ph.D., CEO of CalciMedica, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 9:10 a.m. ET [1] - A live webcast of the presentation will be available on CalciMedica's investor relations website, with a replay archived for 90 days [2]
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference